Katalyze AI Raises $10.5M to Build the Agentic Operating System for Pharmaceutical Companies

Katalyze AI, the agentic operating system for pharmaceutical companies, led by Reza Farahani, Shreyas Becker, has raised $10.5 million in seed funding led by Bonfire Ventures, along with Inovia Capital, Ripple Ventures, Alumni Ventures, and leading angel investors including Gokul Rajaram and Farzad Soleimani. Katalyze’s platform lets any scientist, engineer, or analyst in a biopharma company build teams of agents that take on real engineering, scientific, and manufacturing work.

Why Now: Putting AI Agents to Work in Pharma.

The path from drug discovery to patients has become increasingly complex, costly, and time-intensive. With patent expirations and drug shortages adding pressure on pharmaceutical companies, the need to accelerate development timelines has never been greater.

Katalyze is built to apply AI to pharma’s most demanding scientific challenges, where accuracy and reliability matter more than approximate answers.

Katalyze: One Agentic Operating System for Pharma.

Katalyze is an agentic operating system for pharmaceutical companies, connecting fragmented lab, plant, and enterprise data systems into a unified intelligence layer. Through integrations with MES, LIMS, ELN, historians, and SAP, the platform enables people and AI agents to reason over trusted, traceable data.

Built for regulated environments, Katalyze delivers verified outputs while meeting GxP, privacy, and data sovereignty requirements. Its knowledge graph and ontology layer ground every agent in facility-specific data, enabling accurate and auditable results.

Supported by a network of experienced scientists and engineers, Katalyze helps accelerate pharmaceutical workflows. In one early deployment, an analysis that previously required a year and $4–6 million was completed in 45 minutes.

Key Features:

Operational Data Layer: Unifies fragmented plant and laboratory data into a single source of operational truth, eliminating manual data consolidation.

Primary Production Record: Provides a GxP-native ontology layer and knowledge graph that anchors every agent insight and decision to verified source data.

Katalyze Agent Catalog: Offers prebuilt, domain-trained agents for MSAT, Quality, and bioprocess engineering workflows, including deviation investigations, CAPA tracking, and APQR drafting.

Agent Studio: Enables scientists and data teams to build custom AI agents on the same secure, compliant foundation while maintaining traceability and regulatory standards.

According to Co-Founder and CEO Reza Farahani, Katalyze was built to help pharmaceutical teams accelerate development and manufacturing while maintaining the industry's highest standards for accuracy, security, and compliance. The platform grounds AI agents in immutable data records, enabling faster workflows without exposing sensitive information.

Bonfire Ventures General Partner Brett Queener highlighted Katalyze's infrastructure-first approach, noting that its GxP-native context layer enables AI agents to reason across fragmented pharma data and automate critical manufacturing workflows.

Built by a World-Class Team.

Katalyze was founded by Reza Farahani (CEO), Shreyas Becker (COO), Hannes Bretschneider (Chief AI Officer), and Matt Cruz (Founding Engineer), a team with decades of experience across AI, enterprise technology, and life sciences.

The company has built a network of employees and advisors from organizations including Sanofi, OpenAI, and Johnson & Johnson. The seed funding will support team expansion across engineering, science, and go-to-market, while accelerating the development of domain-trained agents and deployments with leading pharmaceutical companies.